The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; none of the 23 sources its claims cite is checked for support yet.
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Open accessAbstract
BACKGROUND: Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally. OBJECTIVE: To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures. METHODS: A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials. RESULTS: The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Abeta-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures. CONCLUSION: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This ADNI clinical characterization paper reports baseline and 12-month clinical, cognitive, and CSF biomarker data for 819 participants: 229 cognitively normal, 398 with MCI, and 192 with mild AD. It shows expected group differences at baseline, a 16.5% 12-month MCI-to-AD progression rate, and baseline CSF Aβ-42 predicting 12-month cognitive change in normal and MCI groups.
Key findings
- At baseline, ADAS-Cog total scores were 6.2 ± 2.9 in controls, 11.5 ± 4.4 in MCI, and 18.6 ± 6.3 in AD (p < 0.001); MCI subjects were most impaired on memory items and only mildly impaired in nonmemory domains.
- Over 12 months, 64 of 398 MCI subjects progressed to AD, a rate of 16.5% (95% CI 11.9%–20.5%); normal controls progressed to MCI at an estimated 1.4% (95% CI 0%–3.2%).
- ADAS-Cog 12-month change was −0.5 ± 3.0 in controls, 1.1 ± 4.4 in MCI, and 4.3 ± 6.6 in AD (p < 0.001).
- Baseline CSF Aβ-42 decreased across groups (controls 206 ± 5, MCI 164 ± 4, AD 143 ± 4 pg/mL; p < 0.001), and higher baseline Aβ-42 was associated with better ADAS-Cog performance and smaller 12-month change in normal subjects and MCI.
Methods
- Multicenter ADNI cohort of 819 subjects aged 55–90 enrolled at baseline and classified as cognitively normal, MCI, or mild AD using standard clinical, cognitive, and functional criteria; subjects were followed for 12 months with cognitive and functional measures, MRI/PET in subsets, and lumbar puncture in a minimum of 20% per site.
- Baseline group comparisons used nonparametric tests (Kruskal-Wallis) with Hochberg multiple comparisons and exact tests for proportions; 12-month change was summarized as conversion proportion, baseline-to-12-month mean or percent difference, and rate per year from mixed-effects regression models.
- Annual conversion rates were estimated using a hybrid interval-censored method; CSF Aβ-42 was related to diagnosis, ADAS-Cog performance, and 12-month ADAS-Cog change.
Limitations
- The paper states that a 12-month change period is not sufficient to draw conclusions about the likelihood of clinical change, and that the ADNI cohort likely does not represent “typical” community subjects because participants were more highly educated, mostly white, and had a high proportion of APOE4 carriers in the MCI and AD groups.
- The paper also states that the MCI criteria required a stringent degree of memory impairment, so these subjects were likely further along the clinical spectrum and more likely to progress than less-impaired MCI subjects.
- Evident from the text: CSF analyses were limited to subsets (baseline n = 114 controls, 199 MCI, 102 AD), and some subjects lacked 12-month follow-up diagnoses (17 controls and 41 MCI subjects), which limits interpretation of conversion and biomarker results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
53 Own result · 8 Sources not found · 8 Own interpretation · 5 No basis given · 3 Not checked yet · 3 Own method
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“successfully predicted the 12-month change in cognitive measures.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plaincorrelationaln = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but they looked more like the AD group for change in digit span, category fluency, and trail making”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nonmemory cognitive measures were only minimally impaired in the subjects with MCI.”
- Also stated in: § RESULTS Baseline characteristics. · hedged
“The neuropsychological battery indicated that, in general, subjects with MCI were more impaired than controls on the memory items and were only mildly impaired in nonmemory domains (table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS Baseline characteristics. · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The sub-jects with AD were impaired in virtually all of the cognitive areas tested.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These scores indicated, however, that the subjects with MCI gained most of their error points on memory items.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline CSF measures of A-42 separated the 3 groups as expected”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plaincorrelationaln = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The next greatest area of impairment for the subjects with MCI resulted from the executive function domain.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI also remained relatively stable as a group, and the subjects with mild AD showed a decline on most of these measures.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The interaction of A-42 and time also had a significant effect on ADAS-Cog scores in subjects with MCI ( p ϭ 0.00), but not in normal subjects.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 14
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CDR sum of the boxes essentially did not change in the normal control group (0.1) and increased by approximately 0.7 points in the subjects with MCI and 1.5 points in the subjects with AD ( p Ͻ 0.001).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD.”
- Also stated in: § RESULTS Baseline characteristics. · hedged
“These scores indicated, however, that the subjects with MCI gained most of their error points on memory items.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS Baseline characteristics. · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In general, the normal group stayed nearly the same, and the AD group worsened significantly compared to the normal controls.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and more like the normal controls for the clock test and global CDR.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, subjects with MCI had a mean total Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) score of 11.5, while the normal control subjects had a score of 6.2 and the subjects with mild AD had a score of 18.7 ( p Ͻ 0.001, table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“cholinesterase inhibitors-normal controls 0%, subjects with MCI 43.7%, subjects with AD 84.9%”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 819 subjects were recruited and received a baseline evaluation as part of the ADNI study.”
- Also stated in: § RESULTS Baseline characteristics. · plain
“There were 229 normal control subjects, 398 subjects with MCI, and 192 subjects with mild AD enrolled.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS Baseline characteristics. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The estimated premorbid verbal IQ of these subjects was quite high, at almost 120 for the normal control subjects, 116 for the subjects with MCI, and 114 for the subjects with AD.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
hedgedn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In all cases except the Hachinski Scale and Geriatric Depression Scale, the mean scores for the 3 groups differed significantly at p Ͻ 0.001, with normal controls performing best, subjects with AD worst, and subjects with MCI in the middle.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The MCI group was more variable; in most cases they worsened more than the normal group but not as much as the AD group”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Approximately 50% of the subjects with MCI were on antidementia therapies.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most of the subjects in the study were white, and this was approximately equivalent across the groups.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in table 2, the mean age of the 3 groups was equivalent at approximately 75 years.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“there were more men than women in the MCI group (64.6% men vs 35.4% women).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 398- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“There was somewhat less variability on the global measures, while some of the individual neuropsychological tests such as the AVLT showed considerable variability among the subjects despite relatively modest mean group changes.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“CSF A-42 levels were assessed at baseline and were correlated with clinical diagnoses, performance on the ADAS-Cog, and changes in performance on the ADAS-Cog over 1 year (table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Delayed recall improved by 5.3% in the normal control group and declined by 4.8% in the subjects with MCI and 7.2% in the subjects with AD.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“As such, the baseline characteristics of the subjects indicated that the 3 groups were generally well educated, intelligent, and mostly white, and perform in a fashion similar to subjects recruited for typical clinical trials.[25][26][27][28]”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CSF A-42 data correlated with the diagnostic groups in the expected fashion with levels being lower in the subjects with MCI than in the normal subjects.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
None of the sources cited for this claim have been checked yet.
In the paper
“They tend to be more highly educated and the proportion of APOE4 carriers was quite high in the MCI and AD groups but is consistent with subjects recruited for clinical trials.25”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On the memory measures such as the AVLT, there was virtually no change across 12 months in learning in the normal control group with a decreased learning of 1.3 items in the subjects with MCI and 3.7 fewer items learned in the AD group.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An additional 8 subjects with MCI reverted to a normal classification over that interval, and 41 did not have a follow-up diagnosis.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plainn = 398- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“may allow detection of the neurodegenerative process at an earlier point in the spectrum”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [6]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [7]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [8]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All hypothesis tests were 2-sided at level 0.05, and models were validated both graphically and analytically.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Data analysis.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Most investigators believe that Alzheimer disease (AD) is a slowly evolving process that likely begins years to decades before the clinical symptoms are manifest.1”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [1]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A 12month change period is not a sufficient amount of time to draw conclusions regarding the likelihood of clinical change.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“has been a target for clinical trials.[2][3][4][5]”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [2]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [5]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The diagnostic conversions over the 12-month period must be viewed with some caution.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This might be a useful technique to reduce the numbers of subjects used in clinical trials to detect a clinical effect of therapeutic interventions.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
- Rests on an assumption: CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Mild cognitive impairment (MCI) represents an attempt to characterize subjects at an early clinical phase”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [2]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [5]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
The paper relies on this without support.
The expected 12-month progression rate for MCI was approximately 16.5% per year.
“The 12-month progression rate of MCI was as predicted”
“The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year.”
The paper relies on this without support.
The baseline characteristics observed in the recruited cohorts matched the characteristics anticipated for normal, MCI, and AD cohorts.
“The Alzheimer's DiseaseNeuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics.”
The paper relies on this without support.
The MCI subjects have an underlying Alzheimer's disease process that drives clinical progression.
“As such, these subjects were likely further down the clinical spectrum with respect to the underlying AD process such that they would be more likely to progress than subjects with less impairment in the MCI spectrum.”
The paper relies on this without support.
CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
“The CSF A-42 data correlated with the diagnostic groups in the expected fashion with levels being lower in the subjects with MCI than in the normal subjects.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Another issue is that the vast majority of data from PET and CSF are from selected participants recruited through tertiary care dementia centers [176].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“Among the 398 subjects with MCI at baseline, 64 progressed to AD at 12 months”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“Table 5 Baseline measures on subjects according to progression status at 1 year Assortment variable Nonprogressors, mean ؎ SD (n ؍ 329) Progressors, mean ؎ SD (n ؍ 69)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“the subjects with mild AD had a score of 18.7”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“ADAS-Cog total 6.2 Ϯ 2.9 11.5 Ϯ 4.4 18.1 18.6 Ϯ 6.3 14.0 Ͻ0.001 a, b, c”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“subjects with MCI (r ϭ Ϫ0.22; 95% CI Ϫ0.035 to Ϫ0.08)”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“95% CI Ϫ0.035 to Ϫ0.08”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“In all cases except the Hachinski Scale and Geriatric Depression Scale, the mean scores for the 3 groups differed significantly at p Ͻ 0.001”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“GDS Score 0.8 Ϯ 1.1 1.6 Ϯ 1.4 7.3 1.7 Ϯ 1.4 0.6 Ͻ0.001 a, b”
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Self-citationRandom-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
VALIDITY OF THE TRAIL MAKING TEST AS AN INDICATOR OF ORGANIC BRAIN DAMAGE
Reitan, R. M. (1958) · Perceptual and Motor Skills · doi:10.2466/pms.1958.8.3.271 · Cited by 8,167
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citationThe Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Gauthier, S. G., Reisberg, ., Zaudig, M., Petersen, R. C., Ritchie, K. A., Broich, K., Belleville, S., Brodaty, H., Bennett, D. A., Chertkow, H. M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 4,094
Self-citationL’examen Clinique en Psychologie
Rubé, P. (1959) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1959.13.4.989 · Cited by 3,299
Cited by
Sorted by citations
Items 701–800 of 2,570
Sanderlin, A. H., Todem, D., & Bozoki, A. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00164 · Cited by 28
Iwata, A., Iwatsubo, T., Ihara, R., Suzuki, K., Matsuyama, Y., Tomita, N., Arai, H., Ishii, K., Senda, M., Ito, K., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.008 · Cited by 29
Linked CSF reduction of phosphorylated tau and IL-8 in HIV associated neurocognitive disorder
Ozturk, T. T., Kollhoff, A. L., Anderson, A. M. L., Howell, J. C., Loring, D. W., Waldrop‐Valverde, D., Franklin, D. R., Letendre, S. L., Tyor, W. R., & Hu, W. T. (2019) · Scientific Reports · doi:10.1038/s41598-019-45418-2 · Cited by 28
Tabatabaei-Jafari, H., Shaw, M. E., Walsh, E., & Cherbuin, N. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.033 · Cited by 29
Wang, Z.-T., Shen, X.-N., Ma, Y.-H., Ou, Y.-N., Dong, P. Q., Tan, P. L., & Yu, P. J.-T. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.10.078 · Cited by 28
“The specific ADNI diagnostic criteria for distinguishing CN, MCI, and AD participants were summarized in Supplementary Table 4 (Petersen et al., 2010; Thomas et al., 2019).”
Zhang, Q., Du, Q., & Liu, G. (2021) · Journal of Neural Engineering · doi:10.1088/1741-2552/ac37cc · Cited by 29
Rye, I., Vik, A., Kociński, M., Lundervold, A. S., & Lundervold, A. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-18805-5 · Cited by 31
Alzheimer’s disease classification: a comprehensive study
Ayoub, A., Khaoula, E., Benba, A., et al. (2024) · Multimedia Tools and Applications · doi:10.1007/s11042-024-18306-9 · Cited by 28
Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles
Park, M. H., & Han, C. (2014) · International Psychogeriatrics · doi:10.1017/s1041610214002129 · Cited by 29
Evans, S., McRae‐McKee, K., Wong, M. M., Hadjichrysanthou, C., de Wolf, F., & Anderson, R. M. (2018) · European Journal of Epidemiology · doi:10.1007/s10654-018-0381-0 · Cited by 27
“The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a consortium of universities and medical centres in the United States and Canada that have formed a longitudinal observational cohort study to identify new imaging biomarkers measuring AD progression [14].”
BackgroundLi, D., Iddi, S., Thompson, W. K., Rafii, M. S., Aisen, P. S. S., Donohue, M., & Initiative, A. D. N. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.07.008 · Cited by 29
Self-citationJohn‐Williams, L. S., MahmoudianDehkordi, S., Arnold, M., Massaro, T., Blach, C., Kastenmüller, G., Louie, G., Kueider‐Paisley, A., Han, X., Baillie, R., et al. (2019) · Scientific Data · doi:10.1038/s41597-019-0181-8 · Cited by 28
Sarafraz, G., Behnamnia, A., Hosseinzadeh, M., Balapour, A., Meghrazi, A., & Rabiee, H. R. (2024) · ACM Computing Surveys · doi:10.1145/3654664 · Cited by 35
“The Alzheimer’s Disease Neuroimaging Initiative (ADNI) 4 provides two primary datasets: ADNI1 [121] and ADNI2 [8].”
BackgroundRahim, N., El–Sappagh, S., Rizk, H., El-Serafy, O. A., & Abuhmed, T. (2024) · Applied Soft Computing · doi:10.1016/j.asoc.2024.111749 · Cited by 27
van der Veere, P. J., Hoogland, J., Visser, L. N. C., van Harten, A. C., Rhodius‐Meester, H. F. M., Sikkes, S. A. M., Venkatraghavan, V., Barkhof, F., Teunissen, C. E., van de Giessen, E., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209605 · Cited by 33
Enhancing Spatiotemporal Disease Progression Models via Latent Diffusion and Prior Knowledge
Puglisi, L., Alexander, D. C., & Ravì, D. (2024) · Lecture notes in computer science · doi:10.1007/978-3-031-72069-7_17 · Cited by 35
Yan, J., Kim, S., Nho, K. T., Chen, R., Risacher, S. L., Moore, J. H., Saykin, A. J., & Shen, L. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00117 · Cited by 28
Cross‐validation of optimized composites for preclinical Alzheimer's disease
Donohue, M., Sun, C., Raman, R., Insel, P. S., Aisen, P. S. S., Initiative, N. A. A. D. N., Lifestyle, A. I. B. A., & Initiative, J. A. D. N. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.12.001 · Cited by 27
Self-citationSerial position effects in the Logical Memory Test: Loss of primacy predicts amyloid positivity
Bruno, D., Mueller, K. D., Betthauser, T. J., Chin, N. A., Engelman, C. D., Christian, B. T., Koscik, R. L., & Johnson, S. C. (2020) · Journal of Neuropsychology · doi:10.1111/jnp.12235 · Cited by 26
Interactions Between Aging and Alzheimer’s Disease on Structural Brain Networks
Wu, Z., Gao, Y., Potter, T. B. H., Benoit, J. S., Shen, J. F., Schulz, P. E., Zhang, Y., & Initiative, A. T. A. D. N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.639795 · Cited by 29
Mild Cognitive Impairment and Donepezil Impact Mitochondrial Respiratory Capacity in Skeletal Muscle
Morris, J. K., McCoin, C. S., Fuller, K. N. Z., John, C. S., Wilkins, H., Green, Z. D., Wang, X., Sharma, P., Burns, J. M., Vidoni, E. D., et al. (2021) · Function · doi:10.1093/function/zqab045 · Cited by 26
D’Antonio, F., Kane, J. P. M., Ibáñez, A. M., Lewis, S. J. G., Camicioli, R. M., Wang, H., Yu, Y., Zhang, J., Ji, Y., Borda, M. G., et al. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12235 · Cited by 28
3D transfer learning network for classification of Alzheimer’s disease with MRI
Wu, H., Luo, J., Lu, X., & Zeng, Y. (2022) · International Journal of Machine Learning and Cybernetics · doi:10.1007/s13042-021-01501-7 · Cited by 28
Rossi, S. L., Subramanian, P., & Bovenkamp, D. E. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1128619 · Cited by 28
“Data accessibility has been streamlined through disease data sharing initiatives like the Alzheimer’s Disease Neuroimaging Initiative (ADNI) consortium of universities and medical centers in the United States and Canada (Petersen et al., 2010; Alzheimer’s Disease Neuroimaging Initiative, 2023), and the National Eye In…”
BackgroundMethodInfluentialGenetic architectures of cerebral ventricles and their overlap with neuropsychiatric traits
Ge, Y., Wu, B., Zhang, Y., Chen, S.-D., Zhang, Y.-R., Kang, J., Deng, Y., Ou, Y., He, X., Zhao, Y., et al. (2023) · Nature Human Behaviour · doi:10.1038/s41562-023-01722-6 · Cited by 28
The relative efficiency of time-to-threshold and rate of change in longitudinal data
Donohue, M., Gamst, A. C., Thomas, R. G., Xu, R., Beckett, L. A., Petersen, R. C., Weiner, M. W., & Aisen, P. S. S. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.04.007 · Cited by 27
Self-citationAlzheimer's Disease Neuroimaging Initiative in Europe
Frisoni, G. B. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.005 · Cited by 27
Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer’s Disease
Edmonds, E. C., Bangen, K. J., Delano‐Wood, L., Nation, D. A., Furst, A. J., Salmon, D. P., Bondi, M. W., & Initiative, A. D. N. (2016) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617716000928 · Cited by 28
Cerebrospinal Fluid BACE1 Activity and sAβPPβ as Biomarker Candidates of Alzheimer’s Disease
Alexopoulos, P., Thierjung, N., Grimmer, T., Ortner, M., Εconomou, P., Assimakopoulos, K., Gourzis, P., Politis, A. M., Perneczky, R., & Initiative, T. A. D. N. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000488481 · Cited by 27
O’Bryant, S. E., Petersen, M. E., Hall, J. R., Large, S., Johnson, L. A., HABS-HD Study Team, O’Bryant, S. E., Yaffe, K. S., Toga, A. W., Rissman, R. A., et al. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac169 · Cited by 26
Self-citationCortical microstructural associations with CSF amyloid and pTau
Nir, T. M., Villalón‐Reina, J. E., Salminen, L. E., Haddad, E., Zheng, H., Thomopoulos, S. I., Jack, C. R., Weiner, M. W., Thompson, P. M., Jahanshad, N., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02321-7 · Cited by 27
Self-citationKnowledge-guided learning methods for integrative analysis of multi-omics data
Li, W., Ballard, J. L., Zhao, Y., & Long, Q. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.04.053 · Cited by 28
“One notable example is the Alzheimer’s disease neuroimaging initiative (ADNI) study [35], which collected multi-omics data from Alzheimer’s disease (AD) patients, mild cognitive impairment subjects, and elderly controls.”
BackgroundAssociations between misfolded alpha‐synuclein aggregates and Alzheimer's disease pathology in vivo
Binette, A. P., Mammana, A., Wisse, L. E. M., Rossi, M., Strandberg, O. T., Smith, R. A., Mattsson, N., Janelidze, S., Palmqvist, S., ADNI, et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14225 · Cited by 27
Moaveninejad, S., Cauzzo, S., & Porcaro, C. (2025) · Information Fusion · doi:10.1016/j.inffus.2025.102936 · Cited by 26
Abid, M. A., & Munir, K. (2025) · Multimedia Tools and Applications · doi:10.1007/s11042-025-20706-4 · Cited by 26
Initiative, A. D. N., Vuoksimaa, E., McEvoy, L. K., Holland, D., Franz, C. E., & Kremen, W. S. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-018-0019-6 · Cited by 29
“Data were obtained from the ADNI database (http://adni.loni. usc.edu) (Mueller et al. 2005; Petersen et al. 2010).”
BackgroundMethodInfluentialSun, Y., Tan, L., Xu, W., Wang, Z.-T., Hu, H., Li, J., Dong, Q., Tan, L., Yu, J., & Initiative, O. B. O. A. D. N. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200022 · Cited by 27
“Inclusion and exclusion criteria have been described previously [12].”
Learning Cortical Parcellations Using Graph Neural Networks
Eschenburg, K. M., Grabowski, T. J., & Haynor, D. R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.797500 · Cited by 24
Bloch, L., Friedrich, C. M., & Initiative, A. D. N. (2022) · SN Computer Science · doi:10.1007/s42979-022-01371-y · Cited by 34
“…models were evaluated for two AD datasets—the AD subset [14] of the Heinz Nixdorf Risk Factors Evaluation of Coronary Calcification and Lifestyle (RECALL) (HNR) [15] (61 MCI and 59 CN) and 624 subjects (397 MCI, 227 CN) of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) [16] study phase 1.”
BackgroundMethodWang, M., Zou, Q., Sun, Z., Wei, X., Li, P., Wu, X., Li, Y., & Initiative, A. D. N. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01136-y · Cited by 27
Francesco, S. D., Crema, C., Archetti, D., Muscio, C., Reid, R. I., Nigri, A., Bruzzone, M. G., Tagliavini, F., Lodi, R., D'Angelo, E. U., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-43706-6 · Cited by 27
Yaffe, K. S., Tocco, M., Petersen, R. C., Sigler, C., Burns, L. C., Cornelius, C., Khachaturian, A. S., Irizarry, M. C., & Carrillo, M. C. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.12.005 · Cited by 25
Self-citationBarnard, L., Botha, H., Corriveau-Lecavalier, N., Graff-Radford, J., Dicks, E., Gogineni, V., Zhang, G., Burkett, B. J., Johnson, D. R., Huls, S. J., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213831 · Cited by 25
Self-citationAghajanian, S., Mohammadifard, F., Mohammadi, I., Firouzabadi, S. R., Bagheri, A. B., Ghaffary, E. M., & Mirmosayyeb, O. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01827-2 · Cited by 25
Xue, M., Initiative, A. D. N., Sun, F.-R., Ou, Y., Shen, X., Li, H., Huang, Y., Dong, Q., Tan, L., & Yu, J. (2020) · Aging · doi:10.18632/aging.103211 · Cited by 25
Meeker, K. L., Ances, B. M., Gordon, B. A., Rudolph, C. W., Luckett, P. H., Balota, D. A., Morris, J. C., Fagan, A. M., Benzinger, T. L. S., & Waring, J. D. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.10.027 · Cited by 24
“Neuropathological biomarkers that define AD include amyloid plaques and tau neurofibrillary tangles, with the former being detected up to two decades before the onset of cognitive symptoms (Bateman et al., 2012; Jack et al., 2013; Petersen et al., 2010).”
Structural and functional brain alterations revealed by neuroimaging in CNV carriers
Moreau, C. A., Ching, C. R. K., Kumar, K., Jacquemont, S., & Bearden, C. E. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2021.03.002 · Cited by 26
New Drug Design Avenues Targeting Alzheimer’s Disease by Pharmacoinformatics-Aided Tools
Arrué, L., Cigna-Méndez, A., Barbosa, T., Borrego-Muñoz, P., Struve-Villalobos, S., Oviedo, V., Martínez-García, C., Sepúlveda-Lara, A., Millán, N., Montesinos, J. C. E. M., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091914 · Cited by 28
Speech and language characteristics differentiate Alzheimer's disease and dementia with Lewy bodies
Yamada, Y., Shinkawa, K., Nemoto, M., Ota, M., Nemoto, K., & Arai, T. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12364 · Cited by 28
Using proton magnetic resonance spectroscopy to identify mild cognitive impairment
Wang, T., Xiao, S., Li, X., Ding, B., Ling, H., Chen, K., & Fang, Y. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211000962 · Cited by 25
Mapping 3-year changes in gray matter and metabolism in Aβ-positive nondemented subjects
Caballero, M. Á. A., Brendel, M., Delker, A., Ren, J., Rominger, A., Bartenstein, P., Dichgans, M., Weiner, M. W., & Ewers, M. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.007 · Cited by 25
Self-citationAutobiographical Memory Performance in Alzheimer’s Disease Depends on Retrieval Frequency
Müller, S., Mychajliw, C., Reichert, C., Melcher, T., & Leyhe, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151071 · Cited by 27
Structural connectivity centrality changes mark the path toward Alzheimer's disease
Peraza, L. R., Díaz‐Parra, A., Kennion, O., Moratal, D., Taylor, J., Kaiser, M., Bauer, R., & Initiative, A. D. N. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.12.004 · Cited by 24
A blood-based signature of cerebrospinal fluid Aβ1–42 status
Goudey, B., Fung, B. J., Schieber, C., Faux, N. G., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Jagust, W. J., Trojanowki, J. Q., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37149-7 · Cited by 24
Self-citationThomas, K. R., Bangen, K. J., Edmonds, E. C., Weigand, A. J., Walker, K. S., Bondi, M. W., Galasko, D. R., & Initiative, A. D. N. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12238 · Cited by 25
Learning Interpretable Rules for Scalable Data Representation and Classification
Wang, Z., Zhang, W., Liu, N., & Wang, J. (2023) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/tpami.2023.3328881 · Cited by 25
Ulrich, A., Wu, Y., Draisma, H. H. M., Wharton, J., Swietlik, E. M., Cebola, I., Vasilaki, E., Balkhiyarova, Z., Järvelin, M., AUVINEN, J. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44683-0 · Cited by 24
“Clinical descriptions of the cohort and detailed methods for pro fi ling DNA methylation have been published 48,49 .”
MethodProtective effect of bilingualism on aging, MCI, and dementia: A community‐based study
Venugopal, A. L., Paplikar, A., Varghese, F. A., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13702 · Cited by 24
Yoon, D., Myong, Y., Kim, Y. G., Sim, Y., Cho, M., Oh, B., & Kim, S. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120663 · Cited by 25
“This study utilized the 1.5T-3T paired MRI dataset from the Alz-heimer ’ s Disease Neuroimaging Initiative (ADNI) (Jack et al., 2008; Petersen et al., 2010) to perform CNN-based MRI SR and diffusion-based MRI SR.”
MethodIqbal, S., Zhong, X., Khan, M. A., Wu, Z., AlHammadi, D. A., Liu, W., & Choudhry, I. A. (2025) · Information Processing & Management · doi:10.1016/j.ipm.2025.104157 · Cited by 24
Mapping effective connectivity by virtually perturbing a surrogate brain
Luo, Z., Peng, K., Liang, Z., Cai, S., Xu, C., Li, D., Hu, Y., Zhou, C., & Liu, Q. (2025) · Nature Methods · doi:10.1038/s41592-025-02654-x · Cited by 32
Lan, G., Wang, M., González‐Ortiz, F., Zhang, L., Li, A., Li, B., Jiang, M., Yang, J., Chen, X., Shi, D., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00904-3 · Cited by 31
Rajabli, F., Benchek, P. H., Tosto, G., Kushch, N. A., Sha, J., Bazemore, K., Zhu, C., Lee, W., Haut, J., Hamilton‐Nelson, K. L., et al. (2025) · Genome biology · doi:10.1186/s13059-025-03564-z · Cited by 44
Das, S. R., Mancuso, L., Olson, I. R., Arnold, S. E., & Wolk, D. A. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhv022 · Cited by 22
Zhang, Z., Wei, F., Shen, X., Ma, Y., Chen, K., Dong, Q., Tan, L., & Yu, J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.097 · Cited by 26
“The inclusion criteria for individuals without cognitive impairment or with MCI in ADNI was described in detail previously (Bertens et al., 2017; Petersen et al., 2010).”
Xu, W., Initiative, A. D. N., Su, B., Shen, X., Bi, Y., Tan, C., Li, J., Cao, X., Dong, Q., Tan, L., et al. (2020) · Aging · doi:10.18632/aging.103497 · Cited by 24
Serum Calcium Predicts Cognitive Decline and Clinical Progression of Alzheimer’s Disease
Ma, L., Wang, Z., Wang, Z.-T., Hou, X., Shen, X., Ou, Y., Dong, Q., Tan, L., & Yu, J. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00312-y · Cited by 26
“Individuals were excluded if they had Hachinski ischemic score > 4 (a high risk of cerebrovascular disease contributing to cognitive impairment); were unable to undergo MRI; had other neurologic disorders, active depression, history of psychiatric diagnosis, alcohol or substance dependence in the last 2 years; had les…”
InfluentialBangen, K. J., Initiative, A. D. N., Thomas, K. R., Sanchez, D. L., Edmonds, E. C., Weigand, A. J., Delano‐Wood, L., & Bondi, M. W. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201474 · Cited by 24
“Enrollment criteria for ADNI have been previously described in detail [21].”
Houria, L., Belkhamsa, N., Cherfa, A. B., & Cherfa, Y. (2022) · International Journal of Imaging Systems and Technology · doi:10.1002/ima.22824 · Cited by 24
Sadlon, A., Takousis, P., Ankli, B., Alexopoulos, P., Perneczky, R., & Initiative, A. D. N. (2023) · Annals of Neurology · doi:10.1002/ana.26804 · Cited by 26
Classification of Developmental and Brain Disorders via Graph Convolutional Aggregation
Salim, I., & Hamza, A. B. (2023) · Cognitive Computation · doi:10.1007/s12559-023-10224-6 · Cited by 25
Is in vivo amyloid distribution asymmetric in primary progressive aphasia?
Martersteck, A., Murphy, C., RADEMAKER, A. W., Wieneke, C. A., Weıntraub, S., Chen, K., Mesulam, M. M., Rogalski, E. J., & Initiative, A. D. N. (2015) · Annals of Neurology · doi:10.1002/ana.24566 · Cited by 23
Genetic Association of HLA Gene Variants with MRI Brain Structure in Alzheimer’s Disease
Initiative, A. D. N., Wang, Z., Wan, Y., Tan, L., Liu, J., Wang, H.-F., Sun, F.-R., Tan, C., Tan, C.-C., Jiang, T., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9889-z · Cited by 24
Cortical surface‐based threshold‐free cluster enhancement and cortexwise mediation
Lett, T. A. P., Waller, L., Tost, H., Veer, I. M., Nazeri, A., Erk, S., Brandl, E. J., Charlet, K., Beck, A., Vollstädt‐Klein, S., et al. (2017) · Human Brain Mapping · doi:10.1002/hbm.23563 · Cited by 24
Prediction of Cerebral Amyloid With Common Information Obtained From Memory Clinic Practice
Lee, J. H., Byun, M. S., Yi, D., Sohn, B. K., Jeon, S. Y., Lee, Y., Lee, J., Kim, Y. K., Lee, Y., & Lee, D. Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00309 · Cited by 24
Cognitive Profiling Related to Cerebral Amyloid Beta Burden Using Machine Learning Approaches
Ko, H., Ihm, J., Kim, H., & Initiative, A. D. N. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00095 · Cited by 24
“In this study, we used participant data from the ADNI, a multicenter project with approximately 50 medical centers and university sites across the United States and Canada (Petersen et al., 2010).”
MethodMalpas, C. B., Sharmin, S., & Kalinčík, T. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1758087 · Cited by 25
Lussier, F. Z., Benedet, A. L., Therriault, J., Pascoal, T. A., Tissot, C., Chamoun, M., Mathotaarachchi, S. S., Savard, M., Ashton, N. J., Karikari, T. K., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab073 · Cited by 25
“psychological assessments can be used for early detection and monitoring of Alzheimer’s disease dementia.(16) The ADNI study was approved by local Institutional Review”
MethodBoyton, I., Valenzuela, S. M., Collins‐Praino, L. E., & Care, A. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.11.004 · Cited by 23
Adelson, R. P., Garikipati, A., Maharjan, J., Ciobanu, M., Barnes, G., Singh, N. P., Dinenno, F. A., Mao, Q., & Das, R. (2023) · Diagnostics · doi:10.3390/diagnostics14010013 · Cited by 24
“For diagnosing AD within ADNI, key factors were presence of memory complaints, MMSE score (under 27 points), Clinical Dementia Rating (CDR) score (0.5 or 1), and Logical Memory II subscale of the Wechsler Memory Scale–Revised (score up to 25, depending on education level) [36].”
MethodInfluentialWu, Y., Gao, H., Zhang, C., et al. (2024) · Tomography · doi:10.3390/tomography10080093 · Cited by 23
Wen, J., Yang, Z., Nasrallah, I. M., Cui, Y., Erus, G., Srinivasan, D., Abdulkadir, A., Mamourian, E., Skampardoni, I., Hwang, G., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03121-5 · Cited by 31
Self-citationEducational attainment, Aβ, tau, and structural brain reserve in Alzheimer's disease
Cai, Y. Q., Fang, L., Li, A., Yang, J., Zhou, X. Y., He, Z., Sun, P., Wang, Q., Guo, T., & Initiative, A. D. N. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14400 · Cited by 22
Individual bioenergetic capacity as a potential source of resilience to Alzheimer’s disease
Arnold, M., Büyüközkan, M., Doraiswamy, P. M., Nho, K. T., Wu, T., Gudnason, V. G., Launer, L. J., Wang‐Sattler, R., Adamski, J., Initiative, T. A. D. N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57032-0 · Cited by 24
Vermeulen, R. J., Andersson, V., Banken, J., Hannink, G., Govers, T. M., Rovers, M. M., & Rikkert, M. O. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70069 · Cited by 25
“24 ADNI and similarlytheothercohorts,suchastheADC,DESCRIPA,andCREDOS, originate from specialized settings.”
Cognitive disorders in diabetic patients
Koekkoek, P. S., Rutten, G. E. H. M., & Biessels, G. J. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53480-4.00011-4 · Cited by 27
Morales, E. B., Pérez-González, J., Saavedra, K. R., & Medina-Bañuelos, V. (2020) · Computational Intelligence and Neuroscience · doi:10.1155/2020/4041832 · Cited by 25
“Population assignment was carried out as reported in [20] by ADNI experts with the following inclusion criteria for HC: MMSE scores between 24 and 30; CDR of zero; and absence of depression, MCI, and dementia.”
BackgroundMethodResultInfluentialThomas, K. R., Cook, S. E., Bondi, M. W., Unverzagt, F. W., Gross, A. L., Willis, S. L., & Marsiske, M. (2020) · Neuropsychology · doi:10.1037/neu0000694 · Cited by 23
“Specifically, a random sample of predominantly white residents from Olmstead County, MN, were found to have a prevalence estimate of 16% MCI (11.1% amnestic MCI, 4.9% nonamnestic MCI; Petersen et al., 2010) and the Cardiovascular Health Study reported an overall MCI prevalence estimate of 18.”
BackgroundInfluentialGhazi, M. M., Sørensen, L., Sebastien Ourselin, A., & Nielsen, M. (2022) · IEEE Transactions on Neural Networks and Learning Systems · doi:10.1109/tnnls.2022.3177366 · Cited by 24
Sun, L., Li, W., Li, G., Xiao, S., & Initiative, A. D. N. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01653-8 · Cited by 23
Dynamic balance deficit and the neural network in Alzheimer's disease and mild cognitive impairment
Ide, R., Ota, M., Hada, Y., et al. (2022) · Gait & Posture · doi:10.1016/j.gaitpost.2022.01.018 · Cited by 23
Bykova, M., Hou, Y., Eng, C., & Cheng, F. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac208 · Cited by 24
Survey on natural language processing in medical image analysis.
Liu, Z., He, M., Jiang, Z., Wu, Z., Dai, H., Zhang, L., Luo, S., Han, T., Li, X., Jiang, X., et al. (2022) · PubMed Central · doi:10.11817/j.issn.1672-7347.2022.220376 · Cited by 24
Cai, Y., Fan, X., Zhao, L., Liu, W., Luo, Y., Lau, A. Y. L., Au, L. W. C., Shi, L., Lam, B. Y. K., Ko, H., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13083 · Cited by 25
An Alzheimer’s disease category progression sub-grouping analysis using manifold learning on ADNI
van der Haar, D. T., Moustafa, A. A., Warren, S. L., Alashwal, H., & van Zyl, T. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-37569-0 · Cited by 23
Fan, Y., Zhang, Y., Yuan, J., Liu, Z., Zhai, F., Hao, A., Wu, F. Q., Somekh, J., Mor Peleg, B., Zhu, Y., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102247 · Cited by 27
Kumari, R., Das, S., & Singh, R. K. (2023) · International Journal of Systems Assurance Engineering and Management · doi:10.1007/s13198-023-02180-z · Cited by 23
Genetic variation of oxidative phosphorylation genes in stroke and Alzheimer's disease
Biffi, A., Sabuncu, M. R., Desikan, R. S., Schmansky, N., Salat, D. H., Rosand, J. M., & Anderson, C. D. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.141 · Cited by 23
Kawano, N., Awata, S., Ijuin, M., Iwamoto, K., & Ozaki, N. (2012) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.12007 · Cited by 23
The Impact of UNC5C Genetic Variations on Neuroimaging in Alzheimer’s Disease
Initiative, A. D. N., Sun, J., Wang, H.-F., Zhu, X., Yu, W.-J., Tan, C., Jiang, T., Tan, M., Tan, L., & Yu, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9589-0 · Cited by 23
Metadata
- Authors
- Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., Trojanowski, J. Q., & Weiner, M. W.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Neurology
- Published
- 2010-01-19
- Volume
- 74
- Issue
- 3
- Pages
- 201-209
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC2809036
- OpenAlex
- W2122328291
- Cited by
- 2,572
- References
- 27
- Citations by year
- 2026: 312 · 2025: 391 · 2024: 327 · 2023: 254 · 2022: 233 · 2021: 209 · 2020: 182 · 2019: 121 · 2018: 85 · 2017: 67 · 2016: 71 · 2015: 66 · 2014: 45 · 2013: 63 · 2012: 59
- FWCI
- 26.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion)
- PubMed Central (submittedVersion)
- Funders
- Alzheimer's Disease Neuroimaging Initiative (AG024904)
- National Institutes of Health (5r01ag027984-03, 5r01ag030048-05, n01mh22005-16-0-1, 5r01dk075128-05, 5u01ag006786-38, 5r01mh083552-05, 5r01ca104573-05, 5p30ag010124-30, 5p01ag009215-20, 5r01ag011378-25, 5p41rr023953-04, 5u01ag024904-10, 5u01ag029213-05, 5r01ag016381-08, 5r01eb006266-04, 5r01ag010897-27, AG024904, 5p01ag019724-23, 5p30ca093373-23, 5p50ag016574-20)
- National Institute on Aging (AG027984, U01-AG-024904, R01AG11378, P30AG010129, U19 AG010483, U01‐AG10483, R01-AG030048, P50‐AG16574, P01 & AG019724, U01AG06786, P50-AG23501, RC1AG035427, AG 010483, R01AG031224, AG031224, P01 AG 17586-10, 1 U01 AG024904, AG 024904, UO1AG029213-01, P30AG036468, 2 P50 AG016570, 1 U01 AG 024904-05, P30 AG 10124-18, R01 AG031252, P01AG017586, U01AG010483, 1 U01 AG24904, 1P01 AG-19724-07, R01AG027859, P50AG023501, AG027859, P01 AG012435, AG-11378, 2P50AG005133, RC2AG036535, P01-AG19724, P01 AG 09215-20, R01-AG 10897, 2P30AG10129, R01 AG029672, R01 AG16381)
- National Heart, Lung, and Blood Institute (HL-095089, R01HL095089)
- National Institute of Mental Health (U01MH083506, MH 22005, MH062512, MH083506, R01MH079752, R01MH069433, MH083552, MH079752, R01 MH069259, 5 R01 MH071940, MH069433, R01MH072641, P30MH062512)
- National Institute on Drug Abuse (1 R01 DA017830)
- National Cancer Institute (2 P30 CA93373, CA104573)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK075128)
- National Institute of Neurological Disorders and Stroke (1 R01 NS050792, RL1NS062412, P50NS053488, 1 R01 NS049194, RC2NS069368, R01NS031966)
- National Institute of Biomedical Imaging and Bioengineering (1 U54 EB05149, 1 R01 EB 006266-01, U54EB005149, P01EB001955, 5R01EB002138-07)
- U.S. National Library of Medicine (2 R01LM005639)
- National Center for Research Resources (5 P41 RR013642, P41 RR-023953, U24RR021760, U54RR021813, R24 RR021382, R24 RR021992, KL2RR024144)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD050735, 1R01 HD053893-01)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, mild cognitive impairment, neuroimaging biomarkers, cerebrospinal fluid biomarkers, amyloid-beta 42, longitudinal cognitive change, normal aging, memory impairment, ADAS-Cog
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cross-Sectional Studies, Diagnostic Imaging, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
